Q-omics provides the consensus-scored ITSN2 profile across patient tissues and cancer cell-line models. ITSN2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITSN2 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ITSN2 RNA expression shows 20,830 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where ITSN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITSN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITSN2 survival associations across molecular data types. ITSN2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITSN2 RNA expression–survival associations across cancer types. High ITSN2 expression shows unfavorable associations in LGG and MESO, but favorable associations in KIRC, HNSC, LUAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITSN2 RNA expression.
This table summarizes ITSN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITSN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITSN2 shows lower tumor expression in THCA, LUSC, KICH and LUAD and higher tumor expression in LIHC and BLCA. The LIHC box plot shows higher ITSN2 RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p < 0.001).
This table shows molecular features associated with ITSN2 in patient tissues and cancer cell lines. In patient samples, ITSN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITSN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
